Keith W. Pratz, MD

Pratz KW. Humoral influence on cytotoxicity in myeloid leukemia therapies , Haematologica, 111(8): 2026,2558

Wang ES, Erba HP, Zeidan AM, Roboz GJ, Altman JK, Advani AS, Lin TL, Strickland SA, Juckett MB, Pratz KW, Mangan JK, McMahon CM, Alsfeld LC, Balasubramanian SK, Guru Murthy GS, Rotta M, Palmisiano N, McCloskey J, Saliba AN, Khawandanah M, Madanat YF, Naqvi K, Qasrawi AH, Schiller GJ, Badar T, Gojo I, Yaghmour G, Osman D, Zhang H, Tian Y, Soifer HS, Riches M, Corum D, Leoni M, Fathi AT, Issa GC. Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia , Blood: 2026

Pratz KW, DiNardo CD, Arellano M, Thirman MJ, Pullarkat V, Becker PS, Smith BD, Zhang M, Miu K, Potluri J, Pollyea DA Long-Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax-Based Therapies , Am J Hematol, 101(4): 2026,926-929

Ambinder A, Levis M, Wang X, Pratz K, Matthews A. A real-world analysis of the impact of azole antifungal prophylaxis on outcomes in patients with newly diagnosed acute myeloid leukemia treated with venetoclax-based therapy , Leukemia Research, 164: 2026

Foran JM, Sun Z, Luger SM, Claxton DF, Lazarus HM, Arber DA, Rowe JM, Paietta E, Racevskis J, Garrett-Bakelman F, Zhang Y, Altman JK, Al-Kali A, Zheng H, Pratz KW, Broun ER, Powell BL, O'Dwyer KM, Godwin JE, Ofran Y, Litzow MR, Tallman MS. Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial. , Blood Neoplasia, 3(2): 2026

Bhavana Bhatnagar, Zhuoxin Sun, Ryan Mattison, Elisabeth Paietta, Yanming Zhang, Janis Racevskis, Hillard Lazarus, Jacob Rowe, Daniel Arber, Matthew Wieduwilt, Michaela Liedtke, Julie Bergeron, Brent Wood, Keith Pratz, Shira Dinner, Noelle Frey, Steven Gore, Ehab Atallah, Geoffrey Uy, Deepa Jeyakumar, Tara Lin, Cheryl Willman, Nikolai Podoltsev, Daniel Deangelo, Shejal Patel, Michelle Elliott, Anjali Advani, Dimitrios Tzachanis, Pankit Vachhani, Rupali Roy, Elad Sharon, Richard Little, Harry Erba, Richard Stone, Selina Luger, Charles Mullighan, Martin Tallman, Mark Litzow Impact of therapy delays on outcomes in adults with BCR:: ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy+/-blinatumomab , Blood, 146: 2025

Xiaoming Zhong, Kathryn Roberts, Lindsey Montefiori, Zhuoxin Sun, Huimei Wei, Petri Polonen, Ti-Cheng Chang, Wenchao Zhang, Shaohua Lei, Evadnie Rampersaud, Yiping Fan, Gang Wu, Ryan Mattison, Yanming Zhang, Janis Racevskis, Hillard Lazarus, Jacob Rowe, Daniel Arber, Matthew Wieduwilt, Michaela Liedtke, Julie Bergeron, Brent Wood, Keith Pratz, Shira Dinner, Noelle Frey, Steven Gore, Bhavana Bhatnagar, Ehab Atallah, Geoffrey Uy, Deepa Jeyakumar, Tara Lin, Cheryl Willman, Nikolai Podoltsev, Daniel Deangelo, Shejal Patel, Michelle Elliott, Anjali Advani, Dimitrios Tzachanis, Pankit Vachhani, Rupali Roy, Elad Sharon, Richard Little, Harry Erba, Richard Stone, Martin Tallman, Jun J Yang, Elisabeth Paietta, Selina Luger, Mark Litzow, Charles Mullighan Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial , Blood, 146: 2025

Catherine Lai, Thomas Greenwood, E Paul Wileyto, Nisha Singh, Ashlena Livingston, Amanda Lopez, Selina Luger, Alexander Perl, Ximena Jordan Bruno, Elizabeth Hexner, Shannon McCurdy, Saar Gill, Gary Okano, Ali McBride, Carmelo Alonso, Keith Pratz Age-ing study: A prospective evaluation of geriatric, patient-reported and frailty assessments to predict outcomes in older adults with acute myeloid leukemia , Blood, 146: 2025

Eytan Stein, Courtney DiNardo, Amir Fathi, Alice Mims, Keith Pratz, Michael Savona, Anthony Selwyn Stein, Richard Stone, Eric Winer, Christopher Seet, Hartmut Döhner, Dan Pollyea, James McCloskey, Olatoyosi Odenike, Bob Lowenberg, Gert J Ossenkoppele, Mikhail Roshal, Sung Choe, Qian Meng, Stephanie Kapsalis, Prapti Patel, Hagop Kantarjian, Martin Tallman Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH) 1 mutation , Blood, 146: 2025

Ghayas Issa, Amir Fathi, Amer Zeidan, Harry Erba, Gail Roboz, Jessica Altman, Keith Pratz, Mark Juckett, Tara Lin, Suresh Kumar Balasubramanian, Anjali Advani, Gary Schiller, Neil Palmisiano, Marcello Rotta, Stephen Strickland, Christine McMahon, Yazan Madanat, Talha Badar, Mohamad Khawandanah, George Yaghmour, James McCloskey, James Mangan, Antoine Saliba, Ivana Gojo, Diaa Osman, Hongling Zhang, Ying Tian, Marcie Riches, Daniel Corum, Mollie Leoni, Eunice Wang Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007 , Blood , 146: 2025